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Observational studies in humans and experimental studies in animals provide evidence that estrogens protect postmeno-
pausal women against cardiovascular disease.1 However, results 
from randomized clinical trials do not support this contention.1 
The reason(s) for the disparity in the outcome remains unclear 
and unresolved. Multiple factors, including type of estrogen used, 
interaction with progesterone, age of subjects, the status of vascu-
lar disease, and the timing of treatment, have been hypothesized 
to contribute to lack of protective actions in the clinical trials.1,2
On the basis of the conventional mechanism, major 
focus has been directed toward the role of estrogen receptors 
in mediating cardiovascular effects of estrogen, and much 
less attention placed on the contribution, consequence, and 
importance of estrogen metabolism in defining the protec-
tive actions of estrogen, particularly, 17β-estradiol. In this 
issue Pingili et al3 demonstrate that 2-methoxyestradiol, an 
endogenous 17β-estradiol metabolite, attenuates angiotensin 
II–induced hypertension and renal dysfunction in intact male 
and ovariectomized female CYP1B1+/+ mice.3 Previously, 
using CYP1B1−/− mice and pharmacological CYP1B1 inhibi-
tor, their team demonstrated that conversion of endogenous 
17β-estradiol to 2-methoxyestradiol is essential for coun-
teracting angiotensin II–induced hypertension and end-
organ damage (renal and cardiovascular) in female mice.4 
Collectively, their findings provide credence to the original 
hypothesis that 2-methoxyestradiol mediates the protective 
actions of 17β-estradiol on cardiovascular and renal system.2
Aromatase metabolizes testosterone to 17β-estradiol, 
whereas multiple CYP450-isoforms (CYP1A1, CYP1A2, 
CYP1B1, and CYP3A4) convert 17β-estradiol to several 
metabolites.5 The CYP1B1 isozyme is largely extrahepatic 
and dynamically expressed in the vascular endothelial and 
smooth muscle cells. It metabolizes 17β-estradiol to 2- and 
4-hydroxyestradiol, the precursors for 2- and 4-methoxyestra-
diol.5 Oxidative metabolism by CYP1B1 generates free radicals 
and associated with pulmonary hypertension, atherosclerosis, 
renal disease, and glaucoma.2,5–7 Interestingly, sequential con-
version of estradiol to 2-hydroxyestradiol and 2-methoxyestra-
diol by CYP1B1 and catechol-O-methyltransferase (COMT), 
respectively, protects females against cardiovascular disease 
and responsible for sex-based differences.2,4,6 In contrast to 
2-methylation, further oxidation of 17β-estradiol and estrone 
metabolites such as 2/4-hydroxyestradiol, 2/4-hydroxyestrone, 
16α-hydroxyestrone, and 16α-hydroxyestradiol can lead to 
formation of highly reactive quinones and semiquinones, which 
are mutagenic and proproliferative and implicated in hyper-
tension and vascular remodeling associated with occlusion in 
pulmonary hypertension.5–7 Importantly, 2-methoxyestradiol 
blocks semiquinone/quinone formation by inhibiting CYP1B1 
via concentration-dependent feedback mechanism.2 Hence, 
ying-yang balance between protective (2-methoxyestradiol) 
and deleterious (16α-hydroxyestrone or 4-hydroxyestradiol) 
17β-estradiol metabolites may play a critical role in defining 
its protective actions on the cardiovascular system (Figure).
CYP1B1 not only metabolizes 17β-estradiol, but 
also converts testosterone to 6β-hydroxytestosterone 
and 16α-hydroxytestosterone.3 The effects of angioten-
sin II–induced hypertension and end-organ damage in 
CYP1B1+/+, but not CYP1B1−/− male mice, were medi-
ated by 6β-hydroxytestosterone.3 In females, conversion of 
endogenous 17β-estradiol to 2-methoxyestradiol, but not 
4-methoxyestradiol (a 4-hydroxyestradiol product), pro-
tected against angiotensin II–induced hypertension and 
end-organ damage.4 Here, they provide conclusive evidence 
that 2-methoxyestradiol reduces angiotensin II–induced 
hypertension and prevents renal dysfunction in intact males 
and ovariectomized female mice.3 Interestingly, circulat-
ing levels of 2-methoxyestradiol are lower in subjects with 
preeclampsia and inversely correlate with hypertension.8 
Moreover, 2-methoxyestradiol lowers blood pressure induced 
by deoxycorticosterone acetate salt and attenuates hyper-
tension in spontaneously hypertensive and obese ZSF1 rats 
and in animal models for pulmonary hypertension and renal 
toxicity.2,3 The antihypertensive effects of 2-methoxyestra-
diol were accompanied with improvement in endothelial 
function and inhibition of vascular, cardiac, renal, and pul-
monary remodeling associated with the cell proliferation in 
the respective diseases.2,3 Hence, exogenous administration 
of 2-methoxyestradiol is capable of overriding the deleterious 
actions of other hydroxyestrogens and quinone/semiquinones, 
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implicated in the pathophysiology of estrogen-induced pul-
monary hypertension (Figure).7
The metabolism of endogenous 17β-estradiol to beneficial 
or deleterious metabolites may explain the lack of protection 
by estrogen therapy in randomized clinical trials. First, use 
of Premarin, which contains mare urine-derived estrogens has 
negligible amounts of 17β-estradiol, the major endogenous 
human estrogen and 2-methoxyestradiol precursor.6 Second, 
CYP1B1 activity can be influenced by multiple modulators 
(age, hypoxia, mechanical shear and pulsatile stress, dietary 
factors, endocrine disruptors and endogenous phenols, pol-
lutants, lifestyle, eg, drugs and smoking, and genetic poly-
morphism) which may dysbalance the formation of both 
2-methoxyestradiol and the deleterious 17β-estradiol metabo-
lites (Figure).5 Hence, the positive outcome in animals given 
17β-estradiol and housed under controlled conditions would 
be difficult to mimic in humans. Third, the conversion of 
2-hydroxyestradiol to 2-methoxyestradiol by COMT can be 
inhibited by genetic polymorphism and catecholamines.2,5
Although, role of 17β-estradiol–derived 2-methoxyestra-
diol in preventing cardiovascular disease is debated,9 exog-
enous administration of 2-methoxyestradiol clearly prevents 
multiple proliferative disorders, including vascular occlusion, 
atherosclerosis, pulmonary hypertension, systemic sclerosis, 
and cancer.2,3 Hence, 2-methoxyestradiol, in itself, could be an 
important therapeutic agent against proliferative diseases. Risk 
of cancer limits the use of estrogen therapy in postmenopausal 
women. Findings that 2-hydroxylation is protective against 
breast cancer and that 2-methoxyestradiol is anticarcinogenic 
suggest that it may be a safer, noncarcinogenic, substitute for 
treating cardiovascular disease in postmenopausal women.2,5
The intracellular mechanism(s) via which 2-methoxyestra-
diol inhibits cell growth, cell migration, and infiltration of 
macrophages/monocytes and induces apoptosis and anti-
inflammatory effects are well documented.2 However, which 
receptor(s) mediate its effect(s) remains unknown. Interaction 
of 2-methoxyestradiol with colchicine binding site inhibits 
tubulin polymerization, which plays a key role in cell division 
and motility.2 Reportedly, 2-methoxyestradiol binds to GPR30 
(G-Protein–Coupled Estrogen Receptor-30); however, no role 
for GPR30 was found in functional studies.3 Structural simi-
larity of 2-methoxyestradiol to rosiglitazone suggests that it 
may be a PPARγ (peroxisome proliferator-activated receptor 
gamma) ligand.10 Interestingly, 2-methoxyestradiol–induced 
Figure. The ying-yang balance between deleterious and beneficial 17β-estradiol and testosterone metabolites generated by cytochrome-
P1B1 (CYP1B1) and catechol-O-methyltransferase (COMT) in the vasculature. Exogenous 2-methoxyestradiol (2-ME) overrides the 
deleterious actions of endogenous metabolites of testosterone2 and estrogen(s) on hypertension and cardiovascular/renal dysfunction.3 
Moreover, it depicts the conversion of 2-hydroxyestradiol (2OHE2) to 2-ME by COMT, the factors modulating CYP1B1 and COMT activity, 
and the multiple protective effects 2-ME induces and the potential receptors involved. ┴ indicates inhibition; ↑ increase; ↓ decrease; 
and ↔ bidirectional. 17β-HSD indicates 17β-hydroxysteroid dehydrogenase; 6β-OH-T, 6β-hydroxytestosterone; AhR, arylhydrocarbon 
receptor; E1, estrone; and E2, estradiol.
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endothelium-dependent relaxation and phosphorylation of Akt 
(protein kinase B) and eNOS (endothelial constitutive nitric 
oxide synthase) are abrogated when PPARγ was blocked or 
silenced.10 Further examination of 2-methoxyestradiol binding 
sites using sensitive analytic approaches such as proteomics 
would be of considerable value.
On the basis of current data, 2-methoxyestradiol cannot be 
considered a substitute for estrogen therapy. For example, the 
effectiveness of 2-methoxyestradiol against postmenopausal 
symptoms, such as hot flushes, night sweats, osteoporosis, and 
urogenital dryness, and whether it is devoid of prothrombotic 
effects, remains unknown. However, based on its beneficial 
actions, combining 2-methoxyestradiol with existing estrogen 
replacement therapies may potentially increase their benefits.
Because 2-methoxyestradiol is nonfeminizing, the 
possibility that it can override the deleterious actions of 
CYP1B1-derived metabolites of androgens and estrogens on 
hypertension and cardiovascular and renal system suggests 
that it could be of therapeutic importance in both women and 
men. The major challenge in developing 2-methoxyestra-
diol as a useful drug is overcoming its undesirable pharma-
cokinetic properties, that is, poor oral bioavailability and 
short half-life. To develop more potent 2-methoxyestradiol 
analogs, we need to identify its functional receptor and 
transporters.
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